Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. - Wikidata - wikimedia - TriplyDB

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q36175431

about

Renal effects of dapagliflozin in patients with type 2 diabetes Sodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metformin Empagliflozin in the treatment of type 2 diabetes: evidence to date Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives.Dapagliflozin in patients with type 2 diabetes mellitus.Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.Treating the obese diabetic.Complementing insulin therapy to achieve glycemic control.Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice.Responses of renal hemodynamics and tubular functions to acute sodium-glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats.Dapagliflozin for the treatment of type 1 diabetes mellitus.Durability of response to dapagliflozin: a review of long-term efficacy and safety.Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C.Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia.Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels.Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study.Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor.Current practices and future outlook on the integration of biomarkers in the drug development process.Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years.Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.

P2860

Q24564811-44E7A0C8-C953-48A8-A02E-328A327EF16C Q26752815-85745DBE-726D-4493-97DE-C074E5DD9E75 Q34502358-DB73FB94-C89D-4EA8-924C-2BBE6AA1354C Q34609759-2EF69752-7336-4CC5-BE3A-1C9BAB113A0F Q35064363-F1A8FBE7-E671-462F-A0D4-99E83B738FF6 Q35194026-9AF58704-2C1D-45BA-851E-676B15891F8E Q37354187-2BB313E3-D248-49DD-BD68-054DE58C32AB Q38085691-F18B3570-ECBB-4048-BE31-D0844ADCEBDD Q38087696-C8B4CA1C-DA3C-4570-9227-3C6623DD2C93 Q38116766-D705FA81-2395-4F95-A23E-AF83048FE885 Q38163071-CD6CF2AF-0C05-4D26-934D-75C9CDA7A982 Q38311095-B5DF96F3-B318-484C-9E43-3AEA01EFB335 Q38607632-36D1F5EB-9721-41D7-9291-40FB700F9AA1 Q39354776-774F9B71-448A-459C-B15E-19AD0D7135DF Q39430445-767C7EA3-C3DB-41C8-B2F5-C0F052EA7B99 Q39451601-4A91D114-1839-4687-B042-8B41D5B4727F Q39865389-3CF12A21-EF79-4242-8006-12E26CFDF8FB Q40786640-CE943DA7-0342-4958-AC1E-F4B3BDCFF684 Q40914926-FEBFCA22-DA36-4D85-9A71-7C96B9B550B2 Q41678361-C341AB21-B4A3-4D79-9E0C-6640D33B3A6E Q46986653-313080E0-29A1-4CBB-9DED-5B77D77760EB Q47626694-D07CEA00-416A-43BB-B4D8-C83A8035A631 Q48086602-375841BD-8C01-4FA5-A0A9-17DE9152F577 Q51122702-33BAB230-4C7D-4BD0-8541-DAB0D689B050

P2860

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q36175431

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Targeting the kidney and gluco ...... t of type 2 diabetes mellitus.

@ast

Targeting the kidney and gluco ...... t of type 2 diabetes mellitus.

@en

type

label

Targeting the kidney and gluco ...... t of type 2 diabetes mellitus.

@ast

Targeting the kidney and gluco ...... t of type 2 diabetes mellitus.

@en

prefLabel

Targeting the kidney and gluco ...... t of type 2 diabetes mellitus.

@ast

Targeting the kidney and gluco ...... t of type 2 diabetes mellitus.

@en

P1433

Q36175431-851DFC0D-FC25-403E-B67B-1955ACD46D66

P1476

Q36175431-DD1E3D10-8DF3-4DB7-A3B1-61B0E7D0BCAD

P2093

Q36175431-11868980-CE7A-49B5-B13C-FA0934284942

Q36175431-35A71B98-1B52-451E-9D10-6292A393FE2D

Q36175431-453289B0-C068-47B3-A145-ABA9F29AEC64

Q36175431-858480F8-2B6D-4D2B-B2E8-4A24792719A8

Q36175431-A2D16B5A-5D5A-456A-8AE1-2BD8E76575C1

Q36175431-C1659E85-14FD-4219-A91B-A4204B7B7014

Q36175431-E5267C13-8F87-4BBE-AB4A-88991393414C

P2860

Q36175431-0F461831-8508-4D3E-A3C6-D30F3F85543E

Q36175431-13745D84-120E-459D-96D8-4855C49D1F9F

Q36175431-154F3D9B-20D8-4BD8-94D6-515EE8639036

Q36175431-26FC43C2-4BD9-43A4-A85C-3F9C1160C7E6

Q36175431-30A9FFEA-2DC4-4B1A-B00D-28BCEF6AAE8D

Q36175431-3464CFAC-1F7F-433A-810E-A41B144252C8

Q36175431-3F14E723-67AE-4784-8C2C-32C5590664B2

Q36175431-42EDF929-2F0B-41A9-A502-6E18868BF509

Q36175431-46ECB2D5-12C7-4B85-A05F-FE920A3F01B2

Q36175431-4942C55D-9A68-4B78-9C8C-D6BB417A0634

P304

Q36175431-DC0E2873-08FF-4F02-B82A-5392195E483A

P31

Q36175431-47E1A55F-1BE4-4413-86F4-487A5CE36228

P356

Q36175431-2F8602F2-6AF3-4936-8ADF-42E6894B960A

P478

Q36175431-E25E74DF-A32A-4422-ABDD-0E84E2A9C9E8

P577

Q36175431-047B589C-A639-4E69-B736-7379F5C23F74

P5875

Q36175431-CF8498E1-EB67-4809-87A3-9BB0C1B0CC32

P698

Q36175431-A46CE0F0-DB71-4A41-8F73-72CCED971CD9

P921

Q36175431-29DD9182-3148-4F95-B6AA-B28E278CB2A5

P932

Q36175431-490E5263-81E6-4BD0-8D54-B1D633AE13EB

P356

P1433

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

P1476

Targeting the kidney and gluco ...... t of type 2 diabetes mellitus.

@en

P2093

James F List

http://www.w3.org/2001/XMLSchema#string

Jean M Whaley

http://www.w3.org/2001/XMLSchema#string

Joanne Saye

http://www.w3.org/2001/XMLSchema#string

Mark Tirmenstein

http://www.w3.org/2001/XMLSchema#string

Shamik Parikh

http://www.w3.org/2001/XMLSchema#string

Simon M Poucher

http://www.w3.org/2001/XMLSchema#string

Timothy P Reilly

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter

A missense mutation in the Na(+)/glucose cotransporter gene SGLT1 in a patient with congenital glucose-galactose malabsorption: normal trafficking but inactivation of the mutant protein

Active sugar transport in health and disease

10-year follow-up of intensive glucose control in type 2 diabetes

SGLT2 inhibition--a novel strategy for diabetes treatment.

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Physiology of glucose homeostasis.

P304

135-148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DMSO.S22503

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230742842

http://www.w3.org/2001/XMLSchema#string

P698

22923998

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3422910

http://www.w3.org/2001/XMLSchema#string